Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of Akalux-based Illuminox therapy in locally advanced or recurrent head and neck cancer
jRCT1041210120Recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- Dec 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of cetuximab sarotalocan sodium in head and neck cancer (HNC), sponsored by Rakuten Medical, Inc. Primary endpoint: Tumor response per illuminated lesion by tumor volume reduction rate. Started Dec 2021; status: recruiting.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCT1041210120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041210120.